Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants
Authors
Keywords
-
Journal
World Psychiatry
Volume 21, Issue 2, Pages 295-307
Publisher
Wiley
Online
2022-05-07
DOI
10.1002/wps.20972
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
- (2022) Christoph U. Correll et al. npj Schizophrenia
- Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis
- (2021) Giovanni Ostuzzi et al. AMERICAN JOURNAL OF PSYCHIATRY
- An evidence‐splitting approach to evaluation of direct‐indirect evidence inconsistency in network meta‐analysis
- (2021) Ming‐Chieh Shih et al. Research Synthesis Methods
- Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
- (2021) Jose M Rubio et al. SCHIZOPHRENIA BULLETIN
- Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study
- (2021) Marco Solmi et al. SCHIZOPHRENIA BULLETIN
- 20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
- (2020) Heidi Taipale et al. World Psychiatry
- CINeMA: An approach for assessing confidence in the results of a network meta-analysis
- (2020) Adriani Nikolakopoulou et al. PLOS MEDICINE
- The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia
- (2020) Konstantinos N. Fountoulakis et al. CNS SPECTRUMS
- Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
- (2019) Jari Tiihonen et al. JAMA Psychiatry
- Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons
- (2019) Taishiro Kishimoto et al. World Psychiatry
- Patent pooling to increase access to essential medicines
- (2019) Esteban Burrone et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
- (2019) Maximilian Huhn et al. LANCET
- The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples
- (2019) Wolfgang Gaebel et al. SCHIZOPHRENIA RESEARCH
- What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
- (2018) Christoph U. Correll et al. World Psychiatry
- Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial
- (2018) Paola Bozzatello et al. CLINICAL DRUG INVESTIGATION
- Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes
- (2017) Douglas L. Noordsy et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
- (2017) György Németh et al. LANCET
- Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies
- (2017) Taishiro Kishimoto et al. SCHIZOPHRENIA BULLETIN
- Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
- (2017) Heidi Taipale et al. SCHIZOPHRENIA BULLETIN
- Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
- (2017) Christoph U. Correll et al. World Psychiatry
- Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia
- (2017) Jari Tiihonen et al. JAMA Psychiatry
- Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
- (2017) Marco Solmi et al. Therapeutics and Clinical Risk Management
- A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study
- (2016) Peter J. Weiden et al. CNS DRUGS
- Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
- (2016) Adam J. Savitz et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Schizophrenia
- (2016) Michael J Owen et al. LANCET
- Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial
- (2016) Suresh Durgam et al. SCHIZOPHRENIA RESEARCH
- New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base
- (2016) G. Ostuzzi et al. Epidemiology and Psychiatric Sciences
- Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia
- (2016) PN Suresh Kumar et al. Indian Journal of Psychiatry
- Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder
- (2016) Walter Deberdt Therapeutics and Clinical Risk Management
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Ambiguous findings concerning potential advantages of depot antipsychotics
- (2015) Peter M. Haddad et al. CURRENT OPINION IN PSYCHIATRY
- Cardiac effects of sertindole and quetiapine: Analysis of ECGs from a randomized double-blind study in patients with schizophrenia
- (2015) Jimmi Nielsen et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data
- (2015) Kirsty M. Rhodes et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Long-Acting Injectable vs Oral Risperidone for Schizophrenia and Co-Occurring Alcohol Use Disorder
- (2015) Alan I. Green et al. JOURNAL OF CLINICAL PSYCHIATRY
- A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
- (2015) Rajiv Tandon et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: A multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole
- (2015) Jun Ishigooka et al. SCHIZOPHRENIA RESEARCH
- Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
- (2015) Christoph U. Correll et al. World Psychiatry
- Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study
- (2015) G. Ostuzzi et al. Epidemiology and Psychiatric Sciences
- Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia
- (2015) Kenneth L. Subotnik et al. JAMA Psychiatry
- Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia
- (2015) Joris Berwaerts et al. JAMA Psychiatry
- Effectiveness of Paliperidone Palmitate vs Haloperidol Decanoate for Maintenance Treatment of Schizophrenia
- (2014) Joseph P. McEvoy et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder
- (2014) Dong-Jing Fu et al. JOURNAL OF CLINICAL PSYCHIATRY
- Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine
- (2014) Holland C. Detke et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: A randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial
- (2014) Alan M Laties et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Evaluating the Quality of Evidence from a Network Meta-Analysis
- (2014) Georgia Salanti et al. PLoS One
- Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia
- (2014) Qing Rui et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
- (2014) S. Leucht et al. SCHIZOPHRENIA BULLETIN
- A design-by-treatment interaction model for network meta-analysis with random inconsistency effects
- (2014) Dan Jackson et al. STATISTICS IN MEDICINE
- Conceptual and Technical Challenges in Network Meta-analysis
- (2013) Andrea Cipriani et al. ANNALS OF INTERNAL MEDICINE
- Subjective well-being in schizophrenia: A randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER)
- (2013) Dieter Naber et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Equipercentile linking of the BPRS and the PANSS
- (2013) S. Leucht et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Evaluation of inconsistency in networks of interventions
- (2013) A. A. Veroniki et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study)
- (2013) Kunitoshi Kamijima et al. JOURNAL OF AFFECTIVE DISORDERS
- Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia
- (2013) Taishiro Kishimoto et al. JOURNAL OF CLINICAL PSYCHIATRY
- Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies
- (2013) John M. Kane et al. World Psychiatry
- Long-term safety and tolerability of lurasidone in schizophrenia
- (2012) Leslie Citrome et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia
- (2012) John M. Kane et al. JOURNAL OF CLINICAL PSYCHIATRY
- Metabolic Effects of Paliperidone Extended Release Versus Oral Olanzapine in Patients With Schizophrenia
- (2012) Andreas Schreiner et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials
- (2012) T. Kishimoto et al. SCHIZOPHRENIA BULLETIN
- Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database
- (2012) Erick H. Turner et al. PLOS MEDICINE
- Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
- (2012) J. P. T. Higgins et al. Research Synthesis Methods
- Quantifying Clinical Relevance in the Treatment of Schizophrenia
- (2011) Christoph U. Correll et al. CLINICAL THERAPEUTICS
- A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term Treatment
- (2011) John M. Kane et al. JOURNAL OF CLINICAL PSYCHIATRY
- Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of Schizophrenia
- (2011) Robert W. Buchanan et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
- (2011) T Kishimoto et al. MOLECULAR PSYCHIATRY
- International Consensus Study of Antipsychotic Dosing
- (2010) David M. Gardner et al. AMERICAN JOURNAL OF PSYCHIATRY
- Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone
- (2010) Marc De Hert et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
- (2010) Wolfgang Gaebel et al. NEUROPSYCHOPHARMACOLOGY
- Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages?
- (2009) Michela Nosè et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol
- (2009) Steven G. Potkin et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Neurocognitive Effectiveness of Haloperidol, Risperidone, and Olanzapine in First-Episode Psychosis
- (2009) Benedicto Crespo-Facorro et al. JOURNAL OF CLINICAL PSYCHIATRY
- Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study
- (2009) David Hough et al. SCHIZOPHRENIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started